

# The molecular basis for T-type $\text{Ca}^{2+}$ channel inhibition by G protein $\beta_2\gamma_2$ subunits

Seth D. DePuy\*, Junlan Yao\*, Changlong Hu\*, William McIntire\*, Isabelle Bidaud†, Philippe Lory†, Fraydoon Rastinejad\*, Carlos Gonzalez‡, James C. Garrison\*, and Paula Q. Barrett\*<sup>§</sup>

Departments of \*Pharmacology and †Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908; and ‡Département de Physiologie, Institut de Génétique Fonctionnelle, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5203, Institut National de la Santé et de la Recherche Médicale U661, Université Montpellier I et II, 34095 Montpellier, France

Edited by David E. Clapham, Harvard Medical School, Boston, MA, and approved August 1, 2006 (received for review May 12, 2006)

**$\text{G}\beta\gamma$ , a ubiquitous second messenger, relays external signals from G protein-coupled receptors to networks of intracellular effectors, including voltage-dependent calcium channels. Unlike high-voltage-activated  $\text{Ca}^{2+}$  channels, the inhibition of low-voltage-activated  $\text{Ca}^{2+}$  channels is subtype-dependent and mediated selectively by  $\text{G}\beta_2$ -containing dimers. Yet, the molecular basis for this exquisite selectivity remains unknown. Here, we used pure recombinant  $\text{G}\beta\gamma$  subunits to establish that the  $\text{G}\beta_2\gamma_2$  dimer can selectively reconstitute the inhibition of  $\alpha_{1\text{H}}$  channels in isolated membrane patches. This inhibition is the result of a reduction in channel open probability that is not accompanied by a change in channel expression or an alteration in active-channel gating. By exchanging residues between the active  $\text{G}\beta_2$  subunit and the inactive  $\text{G}\beta_1$  subunit, we identified a cluster of amino acids that functionally distinguish  $\text{G}\beta_2$  from other  $\text{G}\beta$  subunits. These amino acids on the  $\beta$ -torus identify a region that is distinct from those regions that contact the  $\text{G}\alpha$  subunit or other effectors.**

$\alpha_{1\text{H}}$  channels | channel regulation |  $\text{G}\beta\gamma$  dimers

Low-voltage-activated (LVA)  $\text{Ca}^{2+}$  currents carried by  $\alpha_{1\text{H}}$   $\text{Ca}^{2+}$  channels play well documented roles in the regulation of neuronal excitability (1).  $\alpha_{1\text{H}}$  currents are important in the perception and transmission of noxious stimuli (2) and in the development of neuropathic pain after peripheral axonal injury (3), and the  $\alpha_{1\text{H}}$  gene (*CACNA1H*) is a susceptibility locus for childhood absence epilepsy (4).  $\alpha_{1\text{H}}$  channels are regulated by kinases (5), redox potential (6), and the activation of G protein-coupled receptors that generate membrane-delimited signals (7–9). For example, in neurons of the dorsal root ganglion, GABA<sub>B</sub> (10), adenosine A1 (11), and dopamine (7) receptor activation produce a steady-state inhibition of  $\alpha_{1\text{H}}$  whole-cell currents. Current inhibition is reproduced by photoreleased GTP $\gamma$ S and blocked by pertussis toxin pretreatment (10) and can be voltage-independent. Thus, dopamine-mediated inhibition is not temporarily reversed by a strong depolarizing pulse and is replicated in excised membrane patches, manifesting as a decrease in the probability of opening of LVA  $\alpha_{1\text{H}}$  channels (7). Analogously,  $\text{G}\beta_2\gamma_2$  dimers elicit a voltage-independent inhibition of  $\alpha_{1\text{H}}$  whole-cell currents carried by recombinant channels by binding directly to the II-III loop of the channel protein (9).

To date, 7  $\text{G}\beta$  and 12  $\text{G}\gamma$  subunits have been identified in mammalian systems, producing a large number of potentially unique dimers that could differ in their interactions among effectors (12). However, the complexity of these signals is mitigated by the reality that the  $\text{G}\beta_{1-4}$  subunits are >85% identical in amino acid sequence (13). Thus, although there are differences in potency and efficacy,  $\text{G}\beta\gamma$  dimers containing any of the  $\text{G}\beta_{1-4}$  subunits can regulate many effectors, such as G protein-activated inwardly rectifying K (GIRK)  $\text{K}^+$  channels (13, 14) and high-voltage-activated  $\text{Ca}^{2+}$  channels (15–18). In surprising contrast, only  $\text{G}\beta\gamma$  dimers containing  $\text{G}\beta_2$  decrease whole-cell currents carried by recombinant  $\alpha_{1\text{H}}$  channels; dimeric isoforms containing  $\text{G}\beta_{(1,3-4)}$  are not modulatory (9).

In this study, we took advantage of this remarkable differential modulation to understand how this selectivity in  $\text{G}\beta$  signaling is achieved. Our results identify a cluster of amino acids that functionally distinguish  $\text{G}\beta_2$  from other  $\text{G}\beta$  subunits and define a region that is distinct from those regions on the  $\beta$ -torus that make contact with the  $\alpha$ -subunit or other effectors.

## Results

$\text{G}\beta_2$ -containing dimers selectively inhibit the activity of  $\alpha_{1\text{H}}$  channels and do not inhibit the  $\alpha_{1\text{G}}$  channel, a T-type  $\text{Ca}^{2+}$  channel homolog (9). Because the II-III loop of  $\alpha_{1\text{H}}$  channels preferentially binds  $\text{G}\beta_2$ -containing subunits and confers current inhibition to unregulated  $\alpha_{1\text{G}}$  channels (9), we hypothesized that modulation of  $\alpha_{1\text{H}}$  channel gating by  $\text{G}\beta_2\gamma_2$  was mediated by the direct binding of  $\text{G}\beta\gamma$  dimers to the channel protein and, thus, would be membrane-delimited. To test this possibility, we measured single-channel currents in membrane patches excised from HEK-293 cells stably expressing  $\alpha_{1\text{H}}$   $\text{Ca}^{2+}$  channels, comparing the effects of pure, recombinant  $\text{G}\beta_2\gamma_2$  and  $\text{G}\beta_1\gamma_2$  dimers (Fig. 1).  $I_{\text{Ca}}$  was activated by a depolarizing pulse to  $-35$  mV, and control activity was monitored for 5–6 min before direct application of either  $\text{G}\beta\gamma$  isoform.  $\alpha_{1\text{H}}$   $\text{Ca}^{2+}$  channels active at  $-35$  mV displayed diverse patterns of small openings (Fig. 1A and B) and full steady-state potential-dependent inactivation (data not shown). After the application of  $\text{G}\beta_2\gamma_2$  to the bath ( $\bar{x} = 2$  nM),  $\alpha_{1\text{H}}$  channels opened less frequently, decreasing the average ensemble current (105 sweeps, concatenated from three cells) to 45.7% of control (Fig. 1A). By contrast, bath application of  $\text{G}\beta_1\gamma_2$  ( $\bar{x} = 2$  nM) did not change the frequency of single-channel opening or decrease the average ensemble current (Fig. 1B).

Fig. 1C illustrates the time course of channel modulation by  $\text{G}\beta_2\gamma_2$  from an exemplar recording of an excised patch with at least two active  $\alpha_{1\text{H}}$  channels. For each sweep, a value of channel open probability ( $NP_o$ ) was calculated from the ratio of the total open time and the test pulse duration.  $\text{G}\beta_2\gamma_2$  markedly decreased  $NP_o$  and concomitantly increased the number of silent sweeps (denoted by a solid circle, Fig. 1C). The decrease in  $NP_o$  ranged from 72% to 27% in seven patches and was accompanied by a  $181 \pm 57\%$  increase in the number of null sweeps (Fig. 1D). This degree of inhibition was close to maximal, because a 10-fold-higher concentration of  $\text{G}\beta_2\gamma_2$  ( $\bar{x} = 20$  nM) only de-

Author contributions: S.D.D., P.L., and P.Q.B. designed research; S.D.D., C.H., and I.B. performed research; J.Y., W.M., F.R., and C.G. contributed new reagents/analytic tools; S.D.D. and P.Q.B. analyzed data; and J.C.G. and P.Q.B. wrote the paper.

The authors declare no conflict of interest.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: GIRK, G protein-activated inwardly rectifying K; HA, hemagglutinin; LVA, low-voltage-activated;  $NP_o$ , channel open probability.


<sup>§</sup>To whom correspondence should be addressed at: Department of Pharmacology, University of Virginia School of Medicine, 1300 Jefferson Park Avenue, Charlottesville, VA 22908. E-mail: pqb4b@virginia.edu.

© 2006 by The National Academy of Sciences of the USA









**Fig. 4.** After residue swapping, recombinant  $G\beta_1PGA\gamma_2$ , but not  $G\beta_2GA\gamma_2$ , inhibits  $\alpha_{1H}$  channel activity in the excised patch. Shown are records and analysis of single-channel  $I_{Ca}$  currents elicited by repeated (6-sec) test pulses to  $-35$  mV from  $-90$  mV (Methods). (A and B) Five consecutive sweeps and the ensemble average of 105 sweeps concatenated from three cells (bottom trace) recorded before (Left) and after (Right) reconstitution of 1 nM recombinant  $G\beta_2GA\gamma_2$  (A) or  $G\beta_1PGA\gamma_2$  (B). (C) Time course of  $NP_0$  from two representative patches. Sequential exposure to vehicle (sweeps 1–50) and in sweeps 51–100  $G\beta_x\gamma_2$  dimer:  $G\beta_2GA\gamma_2$  (Left) or  $G\beta_1PGA\gamma_2$  (Right). Blank/inactive sweeps (nulls) are indicated by filled circles arbitrarily drawn at 0.15 ( $NP_0$ ) for clarity. (D) Bar graphs plot mean  $\pm$  SEM of the percent reduction in  $NP_0$  (Left) or percent increase in nulls (Right) elicited by  $G\beta_2GA\gamma_2$  or  $G\beta_1PGA\gamma_2$  relative to vehicle exposure for each patch. Numbers indicate patches recorded for each condition. \*,  $P < 0.05$  compares vehicle with treatment groups by ANOVA.

independent mutagenesis of P140 and Group A residues removed inhibition, we reasoned that, together, these residues might define a region critical for  $\alpha_{1H}$  channel interaction. In combination with the mutagenesis of A140P, the reciprocal mutation of Group A residues in  $G\beta_1$  conferred channel-inhibitory activity to  $G\beta_1$  ( $G\beta_1PGA$ ; Fig. 3 C and E) that notably was identical to that of wild-type  $G\beta_2$ . Moreover, this set of residues (P140, V178, G179, and A181) produced a channel-inhibitory activity in  $G\beta_1$  that was not mimicked by the  $G\beta_1PGB$  mutant (A140P, Y111F, and N125S), highlighting the specificity of the identified region for channel-inhibitory interactions (Fig. 3E).

Because all  $G\beta(1-4)\gamma_x$  subunits stimulate GIRK1,4 channel activity (13, 14), we tested each mutant in a GIRK1,4 whole-cell channel assay to confirm activity. As expected, both  $G\beta_1$ - and  $G\beta_2$ -containing dimers increased the conductance of GIRK channels equivalently, eliciting an  $\approx 4$ -fold stimulation that was mimicked by  $G\beta$  mutants that either lacked or possessed  $\alpha_{1H}$  channel-inhibitory activity (Fig. 7, which is published as supporting information on the PNAS web site). Thus, residue swapping on blades 2 and 3 of  $G\beta\gamma$  did not disrupt GIRK-effector contact sites that map to other regions of the  $G\beta\gamma$  structure.

Based on our whole-cell studies, we anticipated that the  $G\beta_2GA$  mutations would remove  $G\beta_2$  activity, and the  $G\beta_1PGA$  mutations would confer activity to recombinant proteins tested for direct channel-inhibitory activity. We prepared recombinant  $G\beta\gamma$  protein encoding these mutant sequences. Unlike wild-type  $G\beta_2$ ,  $G\beta_2GA$  failed to decrease single-channel activity (Fig. 4A). Neither the  $NP_0$  nor the number of null sweeps was changed within the 5-min recording period by  $G\beta_2GA$  added to each of seven patches (Fig. 4 A, C, and D). By contrast,  $G\beta_1PGA$  consistently and significantly reduced the single-channel open probability, decreasing  $NP_0$  by  $56 \pm 6\%$  and concomitantly increased the number of silent sweeps by  $186 \pm 50\%$  (Fig. 4 B–D). These changes in single-channel activity fully replicate the inhibitory activity of wild-type  $G\beta_2$ . Thus, candidate sites iden-

tified in our whole-cell studies provide the molecular basis for  $G\beta_2$  inhibitory activity.

## Discussion

It is now well established that ion channels are direct downstream targets of  $G\beta\gamma$  dimers.  $G\beta\gamma$  dimers increase GIRK  $K^+$  currents (13, 14) and persistent  $Na^+$  currents (24) and inhibit high-voltage-activated  $Ca^{2+}$  currents carried by N-, P/Q- and R-type  $Ca^{2+}$  channels (19, 25). We show here that the inhibition of  $\alpha_{1H}$  channels also depends on a direct  $G\beta\gamma$ -channel interaction. Only the dimeric isoform that binds to the II-III loop of  $\alpha_{1H}$  channels,  $G\beta_2\gamma_2$ , inhibits  $\alpha_{1H}$  unitary current in the excised patch, and  $\alpha_{1H}(G_{II-III})$  chimeric channels, to which  $G\beta_2\gamma_2$  cannot bind, are not inhibited by  $G\beta_2\gamma_2$ . However, even though this inhibition is membrane-delimited,  $G\beta_2\gamma_2$  neither slows the kinetics of channel opening to prolong the latency to first opening nor shifts the voltage-dependence of channel activation. Moreover, inhibition cannot be temporarily relieved by a strong depolarizing prepulse. Thus, the inhibition of  $\alpha_{1H}$  channels does not possess the hallmarks of voltage-dependent inhibition of N- and P/Q-type channels transduced by  $G\beta\gamma$  dimers (15, 25).

On the other hand, voltage-independent (VI) inhibition of high-voltage-activated (HVA) channels manifests as a scaled reduction in steady-state current (26) that is not reversed by prepulse (27, 28). VI inhibition does not rely on a direct  $G\beta\gamma$ -channel interaction but, rather, may be the result of either second-messenger-induced phosphorylation and internalization of the channel pore protein (28–30) or the depletion of membrane acidic phosphoinositides ( $PtdIns(4,5)P_2$ ) (26, 31) that destabilizes channel activity. Here, we show that, although  $G\beta_2\gamma_2$  effects a scaled reduction in current and reduces the number of functional channels,  $\alpha_{1H}$  channels are not removed from the plasma membrane, and channel activity is not destabilized in the excised patch configuration, even with  $Ca^{2+}$  chelation. Thus, from our experiments, we conclude that the inhibition of  $\alpha_{1H}$  channels by  $G\beta_2\gamma_2$  defines a unique inhibitory behavior.

Our experiments also identify a cluster of 4 aa (P140, V178, G179, and A181) that can account for the specificity of  $G\beta_2\gamma_2$  action on  $\alpha_{1H}$  channels. The loss of function upon removal of these residues from  $G\beta_2$  and the complementary gain of function upon their transfer to  $G\beta_1$  argues strongly that these residues, located on the outermost strand of blades 2 and 3, are essential for the interaction of  $G\beta_2$ -containing dimers with  $\alpha_{1H}$  channels. By contrast, multiple effector-binding regions on the  $\beta$ -torus have been found to be important for regulating HVA channel activity. Early mutagenesis studies identified residues that cluster on the top surface of the  $\beta$ -torus and along the side of blade 1 within a binding surface shared by the GDP-bound form of the  $\alpha$ -subunit (32). However, other regions that lie opposite to the  $G\alpha$ -interaction surface, containing critical residues Y111 and S189, also have been identified for their importance in  $G\beta\gamma$  subtype-selective potency (33, 34). Nonetheless, these regions are not sufficient to confer inhibitory activity to inactive rat  $G\beta_5$ , suggesting additional critical N-type  $Ca^{2+}$  channel-interacting sites remain to be identified (33). On the other hand, the C-terminal 25 aa of the  $\beta$ -torus can confer full  $G\beta\gamma$  regulation to both P/Q-type  $Ca^{2+}$  channels and GIRK  $K^+$  channels, suggesting that blades 6 and 7 may form a common binding surface on the  $\beta$ -torus for these effectors (35).

Specificity in  $G\beta\gamma$  signaling typically is achieved by coupling specific heterotrimeric G proteins to distinct types of receptors (36) and by unique responses among effector isotypes (36, 37). Our data indicate that specificity can also be determined by unique effector contact sites on the surface of the  $\beta$ -torus. We have identified a set of residues on  $G\beta_2$  that can account for its differential regulation of  $\alpha_{1H}$  channel activity. These residues may not be the only sites of effector contact with  $\alpha_{1H}$  channels, because other residues conserved across all  $G\beta\gamma$  subtypes may also be important structural determinants. Nevertheless, our studies show that  $G\beta\gamma$  subtype-selective activity can be determined by a few residues. This mode of selectivity allows  $G\beta\gamma$  the choice of effector for the transmission of its signal and raises the possibility that, in the dorsal root ganglion, LVA  $Ca^{2+}$  channels are chosen for inhibition by  $G\beta_2$ .

## Methods

**Cell Culture and Transfection.** HEK-293 cells stably expressing  $\alpha_{1H}$  channels were cultured (9) and transiently cotransfected with plasmids for GFP/ $G\gamma_2$ / $G\beta_x$  in a ratio of 1:6:6  $\mu$ g by using CaPO<sub>4</sub> as reported (9). Cells were cultured 2 days before overnight plating for electrophysiological recording made 72 h after transfection (9).

**Molecular Biology.** The residue 140, Group A, and Group B mutations were introduced by using the QuikChange XL Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) (see *Supporting Methods*, which is published as supporting information on the PNAS web site, for primer sequences). All mutations were confirmed by sequencing (University of Virginia Sequencing Facility), and coding regions were excised (BamH1/XhoI) and subcloned into the mammalian expression vector pcDNA3.1.

**Generation of Recombinant  $G\beta_x\gamma_2$ .** The coding regions from all wild-type and mutant  $G\beta_1$  or  $G\beta_2$  constructs (Guthrie Research Institute, Sayre, PA) were excised from pcDNA3.1 by BamH1/XbaI restriction digest and subcloned into pVL1393 baculovirus transfer vector (BD Biosciences/Pharmingen, San Diego, CA). Constructs were validated by restriction enzyme digest, fragment analysis, and sequencing. Recombinant  $G\beta_x$  baculoviruses were generated in Sf9 insect cells by using the BaculoGold system (BD Biosciences/Pharmingen), plaque purified, and a high-titer stock prepared (36). Sf9 cells were infected at a MOI of 3 with high-titer virus encoding for a [His]<sub>6</sub>-tagged  $G\alpha_{i1}$  and the desired  $G\beta_x$  and  $G\gamma_2$  subunits, cell membranes prepared, and the

extracts applied to a  $Ni^{2+}$ -NTA column.  $G\beta_x\gamma_2$  subunits were eluted from the  $Ni^{2+}$ -bound  $\alpha_i$  subunit with AIF, ensuring the recovery of correctly folded  $G\beta\gamma$  dimers (36). The activity of pure  $G\beta\gamma$  dimers was verified by testing for PLC- $\beta$  activation in synthetic lipid vesicles (37).

**Electrophysiology.** HEK-293 cells were recorded as described by using an Axopatch 200A amplifier, and data were collected with PCLAMP 9.2 software.

**Single-channel.** Currents from inside-out excised patches were elicited by a test pulse to  $-35$  or  $-40$  mV from  $-90$  mV (200 msec, 6-sec interpulse) (38). Currents were filtered at 2 kHz and sampled at 100 kHz. The external (pipette) solution was 75 mM CsCl, 60 mM CaCl<sub>2</sub>, and 10 mM Hepes, pH 7.4 (with CsOH). The bath solution was 140 mM potassium-aspartate, 5 mM MgCl<sub>2</sub>, 10 mM EGTA, 20 mM Hepes, pH 7.4 (with KOH), 0.162 mM CHAPS (0.01%), and 0.04 mM DTT. Purified  $G\beta\gamma$  subunits were diluted in bath solution. At the end of each recording, the exact  $G\beta\gamma$  concentration (1–20 nM) was determined from the measured bath volume. Analysis of single-channel records was performed by using Clampfit 9.2 (Axon Instruments/Molecular Devices, Sunnyvale, CA) using the 50% threshold crossing criterion for event detection (further details in *Supporting Methods*).

**Whole-cell.** Currents were elicited as described (9). The internal (pipette) solution was 115 mM CsCl, 1 mM TBACl, 1 mM MgCl<sub>2</sub>, 5 mM Mg-ATP, 1 mM Li-GTP, 20 mM Hepes, pH 7.2 (with CsOH), and 11 mM BAPTA; added CaCl<sub>2</sub> fixed free  $Ca^{2+}$  at 27 nM (0.9 mM). The bath solution was 127 mM TEACl, 10 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub>, 10 mM Hepes, 5 mM dextrose, and 32 mM sucrose, pH 7.4 (with CsOH). Currents were filtered at 2 kHz and sampled at 12.5 kHz, and leak subtraction was performed on line by using scaled hyperpolarizing steps of one-fourth amplitude (P/N4). ANOVA was used for statistical examination with post hoc Dunnett's test, where significance was taken as  $P < 0.05$ . Data are given as mean  $\pm$  SEM.

**Noise analysis.** Tail currents were elicited by  $-70$  mV after repetitive (6-sec) test pulses (6 msec,  $+30$  mV, from  $-90$  mV) from HEK-293 cells stably expressing  $\alpha_{1H}$  channels. The internal (pipette) solution was identical to that described above for whole-cell recording. Bath solution replaced Ca with Ba to reduce charge screening: 117 mM TEACl, 20 mM BaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub>, 10 mM Hepes, 5 mM dextrose, and 32 mM sucrose, pH 7.4 (adjusted with CsOH). Currents were filtered at 5 kHz and sampled at 25 kHz; leak subtraction was performed on line by using scaled hyperpolarizing steps of one-fourth amplitude (P/N4). ANOVA was used for statistical examination with post hoc Dunnett's test, where significance was taken as  $P < 0.05$ .

**Nonstationary Noise (Variance) Analysis.** Briefly,  $[I(t)]$  for each isochrone was used to compute the experimental nonstationary ensemble variance. To correct for basal noise, the average variance at  $-90$  mV was subtracted from that obtained during the test pulse. The subtracted variance ( $\sigma^2$ ) of the tail current ( $-70$  mV) was plotted versus the mean current and the data fitted to  $(20) \sigma^2 = iI(t) - I(t)^2/N$ , where  $i$  = single-channel current amplitude, and  $N$  = number of active channels.  $i$  was obtained from the initial slope and  $N$  from nonlinear curve-fitting analysis performed using Origin (OriginLab, Northampton, MA). The maximum open probability,  $P_o^{\max}$ , was obtained from the relationship:  $P_o^{\max} = I_{\max}/iN$ , where  $I_{\max}$  is the maximum mean current measured in the experiment.

**Surface Expression Measurements.** TSA201 cells cultured in 24-well plates were transiently transfected by using Fugene 6 (Roche, Basel, Switzerland) with plasmids for  $\alpha_{1H}$ -HA, (Ca<sub>v</sub>3.2-HA-GFP-pEGFP-C),  $G\gamma_2$ , and either the  $G\beta_1$  or  $G\beta_2$  at a 1:1:1 ratio (0.5  $\mu$ g of DNA per well). The culture medium (Invitrogen) was

changed 24 h after transfection and the luminometric assay performed as described (22) on 4% paraformaldehyde-fixed cells. Primary and secondary antibodies used for  $\alpha_{1H}$  channel detection were a monoclonal rat anti-HA (clone 3F10; Roche Applied Science) and a horseradish peroxidase (The Jackson Laboratory, Bar Harbor, ME), respectively (further details in *Supporting Methods*). Eleven independent sets of transfections

were performed for each condition and results presented as mean  $\pm$  SEM ( $P < 0.05$ ).

We thank Robert Clay for technical assistance. This work was supported by National Institutes of Health Grants HL36977 (to P.Q.B.) and DK19952 (to J.C.G.). S.D.D. was supported by a predoctoral fellowship from the American Heart Association Mid-Atlantic Affiliate.

1. Perez-Reyes E (2003) *Physiol Rev* 83:117–161.
2. Todorovic SM, Meyenburg A, Jevtovic-Todorovic V (2004) *Pain* 109:328–339.
3. Bourinnet E, Alloui A, Monteil A, Barrere C, Couette B, Poirot O, Pages A, McRory J, Snutch TP, Eschaliere A, Nargeot J (2005) *EMBO J* 24:315–324.
4. Chen Y, Lu J, Pan H, Zhang Y, Wu H, Xu K, Liu X, Jiang Y, Bao X, Yao Z, et al. (2003) *Ann Neurol* 54:239–243.
5. Welsby PJ, Wang H, Wolfe JT, Colbran RJ, Johnson ML, Barrett PQ (2003) *J Neurosci* 23:10116–10121.
6. Fearon IM, Randall AD, Perez-Reyes E, Peers C (2000) *Pflugers Arch Eur J Physiol* 441:181–188.
7. Marchetti C, Carbone E, Lux HD (1986) *Pflugers Arch Eur J Physiol* 406:104–111.
8. Lledo PM, Homburger V, Bockaert J, Vincent JD (1992) *Neuron* 8:455–463.
9. Wolfe JT, Wang H, Howard J, Garrison JC, Barrett PQ (2003) *Nature* 424:209–213.
10. Scott RH, Wootton JF, Dolphin AC (1990) *Neuroscience* 38:285–294.
11. Scott RH, Dolphin AC (1987) *Topics and Perspectives in Adenosine Research, Proceedings of the Third International Adenosine Symposium* (Springer, Munich), pp 549–558.
12. Hildebrandt JD (1997) *Biochem Pharmacol* 54:325–339.
13. Clapham DE, Neer EJ (1997) *Ann Rev Pharmacol Toxicol* 37:167–203.
14. Logothetis DE, Kurachi Y, Galper J, Neer EJ, Clapham DE (1987) *Nature* 325:321–326.
15. Herlitze S, Garcia DE, Mackie K, Hille B, Scheuer T, Catterall WA (1996) *Nature* 380:258–262.
16. Ruiz-Velasco V, Ikeda SR (2000) *J Neurosci* 20:2183–2191.
17. Arnot MI, Stotz SC, Jarvis SE, Zamponi GW (2000) *J Physiol (London)* 527(Pt 2):203–212.
18. Garcia DE, Li B, Garcia-Ferreiro RE, Hernandez-Ochoa EO, Yan K, Gautam N, Catterall WA, Mackie K, Hille B (1998) *J Neurosci* 18:9163–9170.
19. Dolphin AC (2003) *Pharmacol Rev* 55:607–627.
20. Sigworth FJ (1980) *J Physiol (London)* 307:97–129.
21. Alvarez O, Gonzalez C, Latorre R (2002) *Adv Physiol Educ* 26:327–341.
22. Dubel SJ, Altier C, Chaumont S, Lory P, Bourinnet E, Nargeot J (2004) *J Biol Chem* 279:29263–29269.
23. Cabrera-Vera TM, Vanhauwe J, Thomas TO, Medkova M, Preininger A, Mazzoni MR, Hamm HE (2003) *Endocr Rev* 24:765–781.
24. Ma JY, Catterall WA, Scheuer T (1997) *Neuron* 19:443–452.
25. Zamponi GW, Snutch TP (1998) *Curr Opin Neurobiol* 8:351–356.
26. Wu L, Bauer CS, Zhen XG, Xie C, Yang J (2002) *Nature* 419:947–952.
27. Diverse-Pierluissi M, Dunlap K (1993) *Neuron* 10:753–760.
28. Diverse-Pierluissi M, Remmers AE, Neubig RR, Dunlap K (1997) *Proc Natl Acad Sci USA* 94:5417–5421.
29. Tomblar E, Cabanilla NJ, Carman P, Permaul N, Hall JJ, Richman RW, Lee J, Rodriguez J, Felsenfeld DP, Hennigan RF, Diverse-Pierluissi MA (2006) *J Biol Chem* 281:1827–1839.
30. Altier C, Khosravani H, Evans RM, Hameed S, Peloquin JB, Vartian BA, Chen L, Beedle AM, Ferguson SS, Mezghrani A, et al. (2006) *Nat Neurosci* 9:31–40.
31. Gamper N, Reznikov V, Yamada Y, Yang J, Shapiro MS (2004) *J Neurosci* 24:10980–10992.
32. Ford CE, Skiba NP, Bae H, Daaka Y, Reuveny E, Shekter LR, Rosal R, Weng G, Yang CS, Iyengar R, et al. (1998) *Science* 280:1271–1274.
33. Doering CJ, Kisilevsky AE, Feng ZP, Arnot MI, Peloquin J, Hamid J, Barr W, Nirdosh A, Simms B, Winkfein RJ, Zamponi GW (2004) *J Biol Chem* 279:29709–20717.
34. Tedford HW, Kisilevsky AE, Peloquin JB, Zamponi GW (2006) *J Neurophysiol* 96:465–470.
35. Li X, Hummer A, Han J, Xie M, Melnik-Martinez K, Moreno RL, Buck M, Mark MD, Herlitze S (2005) *J Biol Chem* 280:23945–23959.
36. McIntire WE, MacCleery G, Garrison JC (2001) *J Biol Chem* 276:15801–15809.
37. Myung CS, Yasuda H, Liu WW, Harden TK, Garrison JC (1999) *J Biol Chem* 274:16595–16603.
38. Barrett PQ, Lu HK, Colbran R, Czernik A, Pancrazio JJ (2000) *Am J Physiol* 279:C1694–C1703.